• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:

    公开号:SU818489A3
    申请号:SU792822051
    申请日:1979-09-27
    公开日:1981-03-30
    发明作者:Лаурент Хенри；Эсперлинг Петер；Капп Йоахим-Фридрих；Вихерт Рудольф
    申请人:Шеринг Аг (Фирма)；
    IPC主号:
    专利说明:

    (54) A METHOD FOR OBTAINING CORTICOID-21-SULPHOPROPIONIATES OR THEIR SALTS OF THE ACID WITH COMPOUNDS containing the hydroxy group 2. The purpose of the invention is to expand the range of means of action on a living organism, which are hormonal preparations. This goal is achieved by the fact that the compounds of the general formula where ...., A, B, and, V, X, Z have the above values, are brought into interaction with the 3-sulfopropionic acid anhydride of the formula "oA. and the resulting corticoid-21-sulfopropionates are converted to their salts. The process is usually carried out in. organic solvent. Suitable for the process sol erator are, for example, hydrocarbons such as benzene or toluene, halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, ethylene dichloride or tetrachloroethane, ethers such as diisopropyl ether, tetrahydrofuran, dioxane or dimethoxyethane, or ketones such like acetone or methyl isobutyl ketone. . npiouecc is preferably carried out at a temperature from 0 to. Per 1 mol of the pericoid, I use mainly 1.1-10 mol of 3-sulfopropionic anhydride. The resulting corticoid-21-sulfopropionates can be converted to salts, for example, alkali metal salts (mainly lithium, sodium or potassium salts), alkaline earth metal salts (mainly minerals or calcium salts) or amines. Suitable amines are, for example, aliphatic, cyclochipheral or araliphatic. Amines with 1-8 aTOMciMH carbon and heterocyclic amines, for example mono-, di- and triethylamine, mono-, di- and trimethylamine, yuno-, di- and triisopropylamine ethyl dimes, benzyl people , 4-dimethylpiperazine, 1-n-butylpiperidine, 2-methylpiperidine, 1-methyl-2-methylpiperidine, further such amines with water-soluble or hydrophilic groups, such as mono-, di- and triethanolamine, ethyldiethanolamine, N-butyl monoethanolamine, 2-amino-1-butanol , 2-amino-2-ztil-1, 3-propandiol, 2-amino- "-2-methyl-1-propandiol, phenylmonoethanolamine, p-tert-amylphenyldiethanolamine, galactsts 1in, N-methylglucosamine, ephedrine, phenylephedrine, epinephrine, procaine, 2- (4-tert-butyl-2, 6-dimethylphenyl-methyl) -imidazoline. -New corticoid-21-sulfopropionates and, in particular, their salts differ from unsubstituted 21-oxycorticoids in that they are highly soluble in water. Their aqueous solutions are so stable that they can be subjected to hot sterilization and, at the same time, these compounds are very quickly cleaved to active corticoids after intravenous administration. Example 1. A. To a solution of 4.5 g of anhydride of 3-sulfopropionic acid in 150 ml of methylene chloride are added 4.5 g of 6O6-fluoro-11 | b, 21-dioxy-166-methyl-1, 4-pregnadien-3, 20-dione. And 2 hours stirred in an ice bath. The precipitate formed after decanting the methylene chloride phase is dissolved in 100 ml of water. The aqueous solution is sequentially extracted by shaking, respectively, with 100 ml of a mixture of methylene chloride and isopropyl alcohol in a ratio of (9: 1), (8: 2), (7: 3) and (6: 4). From the extract, which is obtained with a mixture (7: 3), after evaporation in vacuo, 4.2 g of boO-11-oxy-lbol -methyl-21- (3-sulfopropionyloxy) -i, 4-pregnadiene-3, 20 are obtained -dione. V. 513 MG | Boob-fluoro-11p -oxy-1bc -methyl-21- (3-sulfopropionyloxy) -1, 4-pregnadien-3, 20-dione is dissolved in 10 MP of distilled water and titrated with pH control using a glass electrode 0 , 1 n ,. sodium hydroxide solution to a pH of 7.0. The salt solution is extracted three times by shaking with 50 ml of diethyl ether each time and then freeze-dried under vacuum at 0.1 mbar. 496 mg of sodium salt of () O-fluoro-11 (L-oxy-1bA-metsh1-21- (Z-sulfopionyloxy) -1, 4, Prednadi € H-3, 20-dione as a friable white powder are obtained. T mp 190-200 p. + 94 ° (methanol), UV: b. 7b (methanol). Example 2. 802 mg 6o-fluoro. -11 | -oxy-16o-methyl-21- (3 -sulfo-propionyloxy ) -1,4-pregnadien-3.20 dionic aqueous OD with a solution of caustic potash under the conditions of Example 1-B and converted into the potassium salt. Exit 698 Mp 190-200 s pf-J + 94 ° (water) UV: Ey4a 14200 (methanol). Example 3, 461 mg of bs6-fluoro - y. | b-hydroxy-1bo methyl-21- (3-sulfopropionyloxy) -, 4-pregnadien-3, 20 dione with water 0, 1 N. solution. Hydroxide of lithium at In Example 1, the conditions were converted to lithium salt. Yield 370 mg, mp 200-210 ° C EctJJ +99 (water). UV: 13500 (methanol). Example 4. 513 mg BL-fluoro- 11-oxy-16v-methyl-21- (3-sulfopropionyloxy) -1,4-pregnadiene 3, 20 dione with aq. 0.1N solution of hydrommonium hydroxide under the conditions specified in example 1-Under conditions converted into the ammonium salt Yield 440 mg, mp 169176 C. + 100 (water). UV: 14,900 (methanol). Example 5. A. 4.5 g 6aJ, 9-d fluorine-Ir), 21-dioxy-16o methyl-1,4-pregnadien-3, 20-dione with the conditions indicated in example 1-A are converted to ba , 9-difluoro ll bH-oxy-16Q -methyl-21 .- (V-sulfopropionyloxy) -1,4-n9egnadiene-3 20-dione. Yield 3.32 g (triturated with diethyl ether). M.p. 222-227s (with decomposition). B. Under the conditions described in Example 1-B, conditions of 1.06 g of bo ;, 9-difluoro-11 / L-hydroxy-1b0 methyl-21- (3 -sulfopropionyloxy) -1,4-pregnadien-3,20-dione converted to sodium salt. The output of 870 mg. M.p. 200-225 ° C. Co «+9 p (methanol). UV: .239 16000 (methano Example 6. 796 mg 6oi, 9-difluoro-11 hydroxy-160y-methyl-21- (3-sul-fopropionyloxy) -, 4-pregnadien-3, 2-dione with the values indicated in example 1- Under conditions transformed with aqueous 0.1N solution of potassium hydroxide into potassium salt. Yield 300 mg, mp 207-215 ° C (water). UV: base 15900 (methanol). Example 7. 530 mg 6 °, 9- difluoro-11 | L-hydroxy-16o methyl 21- (3 -sulfopropionyloxy) -1,4-pregnadiene-3,20-dione with the aqueous 0, ljj. solution of lithium hydroxide indicated in example 1-C to lithium salt - Yield 498 mg, mp 210-220s. tPb.lt) +98 (water). UV: 15400 - (methanol). Example 3. 638 mg of 6Y, 9-difluoro-11 | ) coxy-16o -methyl-21- (3-sulfopropionyloxy) -1,4-pregnadium-3,20 -dione with the conditions indicated in Example 1-In aqueous conditions 1 n. Acmonium hydroxide solution is converted to ammonium salt. M.p. 168-184c.rcii3i + 104 ° (water). UV: Cisg 16000 (methanol). Example 9. 531mg 6y, 9-difluoro-11 | -oxy-16o -methyl-21- (3 -sulfopropionyloxy) -1,4-preng-1-dien-3,20-dione under the conditions specified in Example 1-In aqueous 0.04 n. with a solution of hydroxide, kshihtsi conversion to calcium salt. Yield 456 mg. + 93 (water). UV: 520 29200 (methanol). Example 10 A. A. 4.5 g 11,17, 21-trioxy-1,4-pregnadien-3, 20-dione under the conditions indicated in Example 1-A are converted to 11,17-dioxy-21- (g -sulfopropionyloxy) -1,4-pregnadien-3, 20-dione. Vcode 2.28 g. B. 680 mg, 17-dioxy-21- (V-sulfopropionyloxy) -1,4-pregnadien-3, 20-dione, as described in Example 1, are converted to sodium salt. Yield 500 mg. M.p. 180-2 (with decomposition). Loi + 79 (methanol). UV: 6243 - 10,600 (methanol). Example 11. A. 1.0 g 11 / i, 17,21-trioxy-6a -methyl-1,4-pregnadien-3, 20-dione under the conditions described in Example 1-A are converted to Ilj2i 17-dioxy -6C1 -methyl-21- (3-sulfopropionyloxy) -1,4-pregnadien-3,2 0-dione. Output 600 mg. E. 580 mg of 11p, 17-dioxy-6o-methyl-21- (3 -sulfopropionyloxy) -1,4-pregnadien-3, 20-dione, under the conditions described in Example 1-B, the conditions are converted to the sodium salt. Yield 470 mg. T. pl. 206-224 C. + water). UV: 243 13100 (methanol). Example 12. A. 3.0 g of 9-fluoro-11 | b, 21-dioxy-16o, 17-isopropylidenedioxy-1, 4-pregnadien-3, 20-dione at. the conditions described in Example 1-A were converted to 9-fluoro-11-hydroxy-16o, 17-isopropylenedioxy-21- (3-sulfopropionyloxy) -, 4-pregnadien-3,20-dione. Output 2 1 g. B. 742 mg of 9-fluoro-11 hydroxy-16C3, 17g -isopropylidenedioxy-21- (3 -sulfopropionyloxy) -1,4-pregnadiene-3,20-dione under the conditions described in Example 1-B converted to sodium salt. Yield 704 mg. M.p. 238-243 ° C. + 93 (water). UV: anol). Example 13. A. 2.5 g of 9-fluoro11)), 17,21-trioxy-16C1 -methyl-1,4pregnadien-3, 20-dione, under the described example 1-A, conditions are converted into -fluoro-11 / B, 17-dioxy-1bO-methyl-21 (3-sulfopropionyloxy) -1,4-prenadien-3, 20-dione. The yield is 992 mg. H. 350 mg of 9-fluoro-11p), 17-dioxy-16CY-methyl-21- (3-sulfopropionylok) -1,4-pregnadien-3, 20-dione, as shown in Example 1-In conditions, transfer to sodium salt . Yield 90 mg. +81 (water). UV: 215 14200 (methanol). Example 14. A. 2.5g 9-chloro-C 2 -F.T.-I, 21-dioxy-16a-methyl-1, 4-pregnadien-3, 20-dione under the conditions described in Example 1-A translate in 9-chloro-6c-fluoro-11 (-oxy-1b 11 -methyl-21- (3 -sulfopropionyloxy) -1, 4-pregnadien-3, 20-dione. Yield 1.96 g (after trituration with diethyl ether 54 mg of 9-chloro-b (/ - fluorine-11 hydroxy-160i-methyl-21- (3 -sulfopropionyloxy} -1, 4-pregnadien-3, 20-dione under the conditions described in example 1-B converted to sodium salt. Yield 508 mg. Mp. 201-230 C (with decomposition). M +122 "(water). UV: B, 15000 (methanol). Example 15. A. 1.1 g 9-fluoro-11p, 21-DIOXI-166-methyl-1,4-pregnadien-3, 20-dione p and the conditions described in Example 1-A are converted to 9-fluoro-11E-hydroxy-16o -methyl-21- (3-sul propionyloxy) -1,4-pregnadiene-3.20-dione. Yield 460 mg. 460 mg of 9-fluoro-11-oxy-16a -methyl-21- (3 -sulfopropionyloxy) -1, 4-pregnadiene-3,20-dione under the conditions indicated in example 1-B were transferred to the sodium salt, yield 427 mg, mp 189-200 ° C. Mp +103. (water). 9 14300 (methanol). Example 16. A. 2.0 g of 9-fluoro-11 (, 17,21-tricyxy-1-6 | g-methyl-1,4-pregnadien-3, 20-dione with the procedure described in the example) 1-A conditions x is converted to 9-FTOR-1115,17-dioxy-16 P-methyl-21- (E-sulfopropionyloxy) -1,4-pregene diene-3,20-dione. Yield 970 mg. B. 970 mg of 9-fluoro-11p, 17-dioxy-1br -methyl-21- (3 -sulfopropionyloxy) -1, 4-pregnadien-3, 20-dione with the conditions specified in example 1-B converted into sodium salt. Yield .742 mg. M.p. 205-220C. VDv +8 (water). UV: 6-235 13200 (methanol). Example 17. A. 2.0 g 11) b, 17 21-trioxy-4-pregnen-3,20-dione, under the conditions described in Example 1-A, are converted to ph, 17-dioxy-21- (3-sulfonyl propionyloxy) -4-pregnen-3, 20-dione. Yield 520 mg. B. 520 mg 11p), 17-dioxy-21- (3 -sulfopropionyloxy) -4-pregnen-3, 2-dione with the conditions described in Example 1-C, are converted to sodium salt. The yield is 382 mg. + 123 ° (water). UV: 6; j7, 14400 (methanol). Mp. 192210 p. Example 18. A. 1.0g 9-fluoro-Ip), 17,21-trioxy-4-pregnen-3,20-dione, under the conditions described in Example 1-A, are converted to 9-fluoro-11p, 17- Dioxy-21- (3 -sulfopropionyloxy) -4-pregnen-3, 20-dione. yield 900 mg. B. 900 mg of 9-fluoro-11p, 17-dioxy-21- (3-sulfopropionyloxy) -4-pregene-3, 20-dione, as described in Example 1-B, are converted to sodium salt. Yield 610 mg. M.p. 205250c .. +109 ((water). 14300 (methanol). Example 19. A. 2.5 g of 9-fluoroE, 21-dioxy-16 -methyl-17-vgserylxi-1, 4-pregns1Dien-3,20- dion when written in example 1-A conditions peevod t in 9-fluoro-11 hydroxy-16 methyl21 (3-sulfopropionyloxy) -17-val- (, rhyloxy-1,4-pregnadien-3,2 0-dione. Exit 2.37 g. B. 390 mg of 9-fluoro-11-doxy-16 -methyl-21- (3 -sulfopropionyloxy) -17-valeryloxy-1, 4-pregnadien-3, 20 dione with the conditions described in Example 1-B x is converted to the sodium salt. Yield 550 mg, mp 190-193 ° C. C. VD25 +81 (water) UV: 339 14600 (methanol), Example 20. 1.4 g 9-fluoro-11% oxy-16 -methyl-21- (3-sulfopropionyloxy) -17-valeryloxy-1,4-p Egnadien-3, 20-dione with the conditions specified in Example 1-1 is converted into aqueous 0.1 N solution of potassium hydroxide solution in an organic salt, yield 960 mg, mp 1962000 s +78 (water). UV: 240 14900 (methanol). Example 21 A. 1.9 g of 17-butyryloxy-11 b, 21-dioxy-4-pregnen-3, 20-dione under the conditions described in Example 1-A are converted to 17-butyrylox; and-11-oxy-21- (3-sulfopropionyloxy) -4-pregnen-3, 20-dione. Output 600 mg. B. 500 mg of 17-buTyryloxy-11-oxy-21- (3 -sulfopropionyloxy) -4-pregnen-3, 20-dione, as described in Example 1-Under conditions, are converted to sodium salt. Yield 300 mg. T..PL. 2302530s (with decomposition) .o; J | 5 + 68 ° (water). UV: 239 15800 (methanol). Example 22. A. 1.0 g god-fluorine - 11, 17,21-trioxy-1,4-preg-Schien-3, 20-dione in the conditions indicated in Example 1-A are converted into B L-ot-llf i , 17-DIOXI-21- (3 -sulfopropionyloxy) -, 4-pregnadien-3, 20-dione. , Yield 590 mg. B. 500 mg of 60-fluoro-11p), 17-dioxy-21- (-sulfopropionyloxy) -, 4prednadien-3, 20-dione, as indicated in Example 1-C, are converted to the sodium salt. Yield 450 mg. M.p. 230-273 ° С (with decomposition). (water). 13300 (methanol). Example 23. A. 490 mg /, 17a, 2 -trioxy, O-homo-, 4-pregnadien-3, 20-dione, under the conditions indicated in Example 1-A, are converted to, 17-dioxy-2 - (3-sulfopropyloxy ) -O-Homo-, 4-pregns1diene-3,20-dione. Yield 290 mg. B. 290 mg of 1,17a-dioxy-21- (3-sulfopropionyloxy) - D-rov o-1, 4 -pregnadien-3, 20-dione, under the conditions indicated in the example, are converted to sodium salt under conditions. Yield 250 mg. T, Shch1 ,, .. 220-274 0 (with decomposition). , (methanol). UV: & 444 -40,700 (methanol). Example 24. A. 495 mg of 9-flu-11 |, 17a, 21-trioxy-0-homo-1,4-pregnadien-3, 20-dione under the conditions indicated in Example 1-A are converted to 9-fluoro -11 | 2,17a-dioxy-21- (3 -sylphospionic) -D-homo-l, 4-prognosis-3,20-dione. Yield 440 mg. ,.AT. 440 mg of 9-fluoro-11, 17a-dioxy-21- (3-sulfopropionyloxy) -0-homo -1,4-pregnadien-3,20-dione, under the conditions specified in Example 1-B, are converted to the sodium salt. Output 370 m. 235-283 ° С (with decomposition). MF (methanol). UV: 6240 13400 (methanol). Example 25. A. 500 mg of 6-chloro-11 D 7,21-TRIOXI-1,4, 6-pre1 sodium-3,20-dione under the conditions described in Example 1-A are converted to 6-chloro-11L 17 -dioxy-21- (sG -sulfopropionylox -1,4,6-pregnatriene-3, 20-dione. Yield 380 mg. B. 380 mg 6-chloro-11,17-dioxy-21- (3-sulfopropionyloxy) - 1,4,6-pregnatrien-3, 20-dione with the conditions specified in Example 1-B, conversion to sodium salt. Yield: 350 mg., Melting point 190-240 ° C (with decomposition). TXlp +48 ( methanol) .asS 8100, 8000 (methanol). P p-memer 26. A. To a solution of 10 g of 6-chloro-17-hydroxy-1 (X, 2c0-methylene-4, 6-pregnadien-3 , 20-dione in 75 ml of methanol and 75 ml of tetrahydrofuran is added 15 g of calcium oxide and 500 mg of azoisobutyronitrile. A few ml of a solution of 10 g of iodine in 50 ml of tetrahydrofuran and 30 ml of methanol are added dropwise. The remaining solution of iodine is added dropwise over 8 hours. The reaction mixture is diluted with 500 ml of dichloromethane, calcium oxide is filtered off and the filtrate is washed with sodium thiosulfate solution and dried with water over sodium sulfate and evaporated in BjiKyyMe at. 13 g of 6-chloro-17-oxy-21-iodo-1a, 2a (-methylene-4, 6-pregn-dien-3, 20-dione) are obtained. It is dissolved in 130 ml of acetone and 45 ml of acetic acid, 69 are added. MP of triethylamine and heated for 90 minutes with reflux. The solution while stirring is poured into ice-water, the resulting residue is separated and chromatographed on silica gel. 6.1 g of 21-acetoxy-6-chloro-17-hydroxy-1a, 2c1 methylene are obtained. -4, 6-pregneshen-3,20-dione with Tpl. 224s.
    B. In a 2-liter Erlenmeyer flask, 500 ml of a nutrient solution sterilized at 120 ° C for 30 minutes in an autoclave 60 from a 1% Cornstäpe liquor, 1% soybean powder, and 0.005% soybean oil, adjusted to a pH of 6.2, are placed, then a Curvur culture is introduced. laria lunata (NRRL 2380) and 72 hours at 65
    A study of the pharmacological action of the obtained corticoid-21-sulfopropionates is carried out as follows.
    To test with endotoxin shock, 10 rats weighing 100–120 g are removed by removing the adrenal glands and for the next day receive under light ether A – C shaken on a rotary shake unit. This forculture is then added to a 20 liter fermenter containing 15 liters of sterilized at and 1.1% of 1% of 1% liquor from cornstarch, 0.4% starch sugar and 0.005% of soybean oil, adjusted to a pH of 6.2, is added as Silicone antifoam SH and kept at 29 s with air blowing (10 l / min), 0.7 api pressure and stirring (220 rpm) for 24 hours. 1 l of culture fluid is transferred under sterile conditions to 14 l of sterilized , yuck is indicated above. The media is from 1% Kornsteype liquor, 1.25% soybean powder and 0.005% soybean oil and cultivated under the same condition their. After 12 hours, a solution of 15 g of 21-acetoxy-6-chloro-17-hydroxy-1l, 2a g-methylene-4, 6-pregnadien-3, 20-dione in 150 ml of dimethylformamide and 15 ml of dimethylformamide is added and mixed with air. After 26 hours, the contents of the fermenter were washed out in two portions of 10 liters of methyl isobutyl ketone and the combined extracts were evaporated in vacuo at a water temperature of 50 s. The residue is treated with methanol, the insoluble silicone oil is separated, the solution is treated with activated carbon and evaporated until crystallization begins. The crystalline product separated out for the most advanced purification was chromatographed on a column of silica gel using a methylene chloride-acetone gradient and then recrystallized from a mixture of acetone and methanol. Pure 6-chloro-11, 17,21-trioxy-1o, 2a; methylene-4, 6-pregnadien-3, 20-dione (8.1 g) melts at 271-2720s. +273 (methanol). UV: 203 17300 (methanol) C. 1.09 g 6-chloro-11,17,21-trioxy-1C1, 2c-methylene-4,6-pregnadien-3, 20-dione with the conditions indicated in Example 1-A x is converted to 6-chloro-11, 17-dioxy-1a, 2a-methylene-21- (-sulfopropionyloxy) -4, 6-pregn 1 dien-3, 20-dione. Yield 620 mg. 0. 620 mg 6-chloro-11 /, 17-dioxy-1a, 2c1-methylene-21- (3-sulfopropionyloxy) -4, 6-pregnadien-3, 20-dione with the conditions specified in example 1-B t in sodium salt. Output 260 mg. ; "Pl, 238-281 ° C (with decomposition). , MTG-I94 "(methanol). UV: 14000 (methanol).
    5 mg of endotoxin per 100 g of live weight intravenously. Directly after this injection, a corticoid solution is injected. Determined by etSubstance
    A. Derivatives of dexamethasone (-9a-fluoro-11,17a, 21-trioxy-16-methyl-1, 4-pregnadien-3, 20-dione)
    Dexamethasone-21-sodium hemisulfate
    Dexamethasone 21- (o-sulfobenzoate)
    on three
    Dexamethasone 21- (3-sulfopropionate)
    on three
    B. Methylprednioolone derivatives (-11, 17o, 21-tripioxy-6o-methyl-l, 4pregnadien-3, 20-dione)
    Metclprednisolone 21-hemisulphate
    on three
    Methylprednisolone-21- (m-sulfobenzoat
    on three
    Methylprednisolone-21- (3-sulfopropionate) sodium
    C. Diflucortolone derivatives (-6rt, 9c "; - difluoro-11, 21-DIOXI-16-methyl-1, 4-pregnadien-3, 20-dione)
    Diflucortolone-21-sodium hemisulfate
    Diflucortolone-21- (3-sulfopropionate
    on three
    Diflucortolone-21- (jf-potassium sulfopropionate
    0. Derivatives of triamcinolone acetone (-9a: -fop-llj), 21-dioxy-lb, 17a; -isopropylidenedioxy-1, 4-pregnadien3, 20-dione)
    Triamcinolone acetonide-21-sodium phosphate Triamcinolone acetonide-21-hemisuccinate Triamcinolone acetonide-21- (3-sulfopropionate) sodium
    The number of animals that survived after this treatment for 24 hours. The results of the test with endoxin discomf are given in the table.
    Dose, mg / kg
    The number of survival animals
    0-1 2-8 10
    3-9 0-4 5-9
    0-10 0-10
    0-7 6-9
    6-10
    权利要求:
    Claims (2)
    [1]
    The invention The method for producing the corticoid of the propionates of the general formula CHjOCOCHjJOjH ... is a single or double bond, X is a hydrogen atom, a chlorine atom, a fluorine atom or a methyl group; y is a hydrogen atom, a fluorine atom or a chlorine atom, Z is an oxo group, or a hydrogen atom in the ot-position and the hydroxy group in the fi-position, —Y-grouping-SNHdH -,, jj gH-A-b-h 1 / yt ol (and I II -C - Rt -CII, where R is a hydrogen atom, an oxygry na or an acyloxy group containing from 1 to B carbon atoms, R is a hydrogen atom or methane per group, RjH Rjj - an alkyl group I containing from d to 4 amov, or their salts, distinguished by the fact that the corticoid of the general form of CHtOH mules .., A, B, U, V, x, y, z have a higher indication, is introduced into interaction with anhydriH C CH 0 xR3 fti -C or IC HC house of 3-sulfopropionic acid Formulas, g-cHt 00 with subsequent injection of the target product in free form or in the form of s5oli. Priority on the grounds: 04,10.78 - in the position of 6-7 is a simple connection, in position 1 - "- 2. simple and double bond 06.08 .79. - in position 6-7 double bond, in position 1-2 of the methylene group.Sources of information taken into account during the examination 1. Mashkovsky IO Medicinal products, PM PM, MediciN (and , 972, p. 97-108, 119-124.
    [2]
    2.Catenent FRG 2.440.209, l. From 07 Oh, publish. 1976.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU818489A3|1981-03-30|Method of preparing corticoid-21-sulfopropinates or their salts
    Reichstein et al.1943|The hormones of the adrenal cortex
    DE2632677A1|1978-01-26|PROCESS FOR THE MANUFACTURE OF ANDROSTANE-17-ONE DERIVATIVES AND THEIR USE
    US3862194A|1975-01-21|Alkylated 3,20-diketo-d{hu 4{b -steroids of the pregnane series
    HU182049B|1983-12-28|Process for producing d-homo-steroides
    US3534139A|1970-10-13|17alpha - ethynyl - 8alpha - h - delta**5| - estrene - 17beta - ol-3-one,process of preparation,therapeutic administration and intermediates
    US3185682A|1965-05-25|Steroid glucuronides and processes for preparing the same
    PL86797B1|1976-06-30|
    US3045033A|1962-07-17|Water soluble cyclophosphate esters of steroids and process for preparing same
    US3250792A|1966-05-10|19-nor-steroids and process for their manufacture
    US3639392A|1972-02-01|Cardioactive oxido-bufatrienolides
    US3268562A|1966-08-23|Method of phosphorylating hydroxy steroids and products resulting therefrom
    US3073816A|1963-01-15|Process of producing 21-orthophosphates of steroids and the 21-diamide orthophosphate intermediates therefor
    US3134791A|1964-05-26|Cyclopentanophenanthrene compounds and process
    US3169131A|1965-02-09|Process for the preparation of 4-fluorohydrocortisone, 21-acylates and 16-substituted derivatives thereof, and intermediates produced in the preparation thereof
    US3651049A|1972-03-21|17alpha 21 alkenylidene dioxy derivatives of pregnane and process for preparation thereof
    US3153645A|1964-10-20|17alpha, 21-|-steroids and process for the preparation thereof
    US3019243A|1962-01-30|11beta-hydroxy-5beta-pregnane-3, 20-dione bisoximes and the 11alpha-lower-alkyl derivatives thereof
    US3009930A|1961-11-21|6-fluoro-9alpha, 11beta-dihalo-progesterone
    US3832345A|1974-08-27|17-desoxy steroidal pyrazoles and processes of preparing them
    US3781276A|1973-12-25|6-azido-6-dehydro steroids of the progesterone series,methods for their manufacture and intermediates produced therby
    US2419220A|1947-04-22|Derivatives of 3-hydroxy cholanic acid and methods of making them
    US3009929A|1961-11-21|9, 11-halogenated progestins
    US3591611A|1971-07-06|3-oxygenated-17-ureido-androstanes and process
    US3009932A|1961-11-21|6-fluoro-9alpha, 11beta- 21-trihalo-progesterones
    同族专利:
    公开号 | 公开日
    IE48954B1|1985-06-26|
    HU183000B|1984-03-28|
    CS215030B2|1982-06-25|
    DK404879A|1980-04-05|
    EP0010056A1|1980-04-16|
    ES484706A1|1980-06-16|
    GB2034715A|1980-06-11|
    EP0010056B1|1983-08-24|
    CA1127630A|1982-07-13|
    US4296109A|1981-10-20|
    DD146296A5|1981-02-04|
    IE791879L|1980-04-04|
    GR74136B|1984-06-06|
    DE2966092D1|1983-09-29|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3089881A|1957-10-29|1963-05-14|Schering Corp|Sulfocarboxylic acid esters of hydroxylated steroids|
    DE1090207B|1958-04-21|1960-10-06|Chimiotherapie Lab Franc|Process for the preparation of water-soluble corticosteroid derivatives|
    FR1392048A|1964-02-21|1965-03-12|Ile D Etudes Et De Brevets Nov|Manufacturing process of steroid compounds of the androstane and estrane series|
    DE2703543C2|1977-01-26|1985-06-05|Schering AG, 1000 Berlin und 4709 Bergkamen|2l- -11β, 17α-dihydroxy-1,4-pregnadiene-3,20-dione, process for its preparation and pharmaceutical preparations containing this compound|US4472392A|1983-01-21|1984-09-18|The Upjohn Company|Sulfonate containing ester prodrugs of corticosteroids|
    US4469689A|1983-03-30|1984-09-04|The Upjohn Company|Sulfonate containing ester prodrugs of corticosteroids|
    US4588718A|1984-03-28|1986-05-13|The Upjohn Company|Carboxy containing ester prodrugs of corticosteroids|
    US4948533A|1984-03-28|1990-08-14|The Upjohn Company|11a-hydroxy steroid diester|
    CA1310009C|1984-03-28|1992-11-10|John Mark Braughler|Ester prodrugs of steroids|
    AU597723B2|1986-08-21|1990-06-07|J.W. Broadbent Nominees Pty. Ltd.|Sodium scymnol sulphate isolated form shark tissues|
    CA1296322C|1986-08-21|1992-02-25|Takuo Kosuge|Active principle isolated from shark tissue|
    US5250711A|1987-07-16|1993-10-05|The Upjohn Company|Amine salts of alkane-1,n-dicarboxylic acid mono- amides|
    WO1989000558A1|1987-07-16|1989-01-26|The Upjohn Company|AMINE SALTS OF ALKANE-1,n-DICARBOXYLIC ACID MONO-AMIDES|
    DE4334823C2|1993-10-09|1998-09-17|Schering Ag|Process for the production of sulfuric acid half esters of estrogens|
    US20040171070A1|2002-05-20|2004-09-02|Ramagauri Bhikhabhai|Peptide analysis using a solid support|
    JP2005518521A|2001-05-23|2005-06-23|アメルシャム・バイオサイエンシーズ・アクチボラグ|Peptide analysis using solid supports|
    US7074570B2|2001-05-23|2006-07-11|Ge Healthcare Bio-Sciences Ab|Peptide fragmentation|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    DE19782843690|DE2843690A1|1978-10-04|1978-10-04|21-Sulpho-propionate ester derivs. of corticoid steroid - easily soluble in water, giving stable, heat sterilisable solns.|
    DE19792932166|DE2932166A1|1979-08-06|1979-08-06|21-Sulpho-propionate ester derivs. of corticoid steroid - easily soluble in water, giving stable, heat sterilisable solns.|
    [返回顶部]